Pan-Facial Layering of Hyaluronic Acid Filler

Erevna Innovations

Status: Enrolling

Conditions: Aesthetic

Treatments: Device: Restylane Injectables

Study type: Interventional

Funder types: Other

Identifiers

NCT07063511

GAL-2025-LAYER-62

Details and patient eligibility

About

Recent advancements in anatomical studies have enabled a more sophisticated approach to treating patients with facial aesthetic concerns with hyaluronic acid (HA) fillers. For instance, volumizing a specific area of concern may be warranted, but it is essential to understand how the underlying patient anatomy is continuing to laxity and hollowness.

Varying manufacturing technology have offered a range of HA fillers with different physical and chemical properties adapted to different indications, each one tailored to provide a slightly different outcome based on the needs of the patient.

Given these advances in the medical aesthetic field, investigators and clinicians are seeking to develop a new methodology for providing patients with a more tailored and personalized treatment approach. This methodology includes using a pan-facial, multilayering treatment technique that can be employed by injectors once experience is gained with standard techniques.

The goal of this study is to assess the efficacy and safety of layering HA from the Restylane line of soft tissue products to create a more harmonious and complete aesthetics results.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Participants must voluntarily sign and date an informed consent, approved by an independent ethics committee, prior to the initiation of any screening or study-specific procedures.

2. Participants must be adult male or female, at least 18 years old.

3. Participants must be willing and able to comply with procedures required in the protocol.

4. Participants must be in good health as per investigator's judgment based on medical history.

5. Participants must not have uncontrolled systemic disease.

6. Participants do not present with or have a history of any medical condition that may place the participant at increased risk following exposure to hyaluronic acid or interfere with the study evaluation, including:

   • Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function
   • History of facial nerve palsy
   • Infection or dermatological condition at the treatment injection sites
   • Marked facial dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or excessively photodamaged skin

7. Participants do not have history of clinically significant medical conditions or any other reason that the investigator determines would interfere with the participants participation in this study or would make the participant an unsuitable candidate to receive the study medical device.

8. Participants do not have history of an allergic reaction or significant sensitivity to constituents of the study medical device (or its excipients), including local anaesthetic agents found in the product (Lidocaine).

9. Participants must not have tattoos, jewellery, or clothing which obscure the treatment area and cannot be removed.

10. Participants do not have anticipated need for surgery or overnight hospitalization during the study.

11. Participants do not have history of surgical procedures in the face, including any lifting procedure (e.g., facial lift, suture lift, thread lift, brow lift, eyelid and/or eyebrow surgery).

12. Participants have not had, in the last 2 years, facial treatment with semi- permanent or permanent soft tissue fillers (e.g., poly-L-lactic acid, polyalkylimide, polymethylmethacrylate, polytetrafluoroethylene, and silicone), synthetic implantation and/or autologous fat transplantation.

13. Participant has not received treatment with energy-based devices in the last 6 months.

14. Participant has not received soft tissue filler within the last 12 month in the face.

15. Female participants of child-bearing potential must have a negative urine pregnancy test prior to any dose of study drug.

16. Female participants of childbearing potential must practice at least 1 protocol-specified method of birth control that is effective from Baseline through at least 30 days after the last dose or until the end of study, whichever is longer. Female participants of non-childbearing potential do not need to use birth control.

17. Female participants that are not pregnant or breastfeeding and are not considering becoming pregnant or donating eggs during the study or for approximately 30 days after the last dose of study medical device or until the end of study, whichever is longer.

18. Participants must not have been treated with any investigational product within 30 days prior to the first dose of study medical device or is currently enrolled in another clinical study

19. Participants must not be presenting with porphyria.

20. Participants must not present with active disease, such as inflammation, infection or tumours, cold sores in or near the intended treatment sites.

21. Participants must not have bleeding disorders or take thrombolytics or anticoagulants.

22. Participants agree to abstain from taking any over the counter NSAIDs at least two weeks prior to any treatment administration (e.g. Advil)

23. Participants must not have need to take immunosuppressants.

Exclusion criteria

1. Participants with known active COVID infection within 14 days of baseline treatment.
2. Participants has a history of cystic acne.
3. Participant has had or is planning to have dental procedures, including teeth cleaning procedures at least 2 weeks before or after any scheduled treatment administration.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Restylane Injectables

Other group

Description:

Thirty (30) adult (\> 18 years) participants, including fifteen (15) participants with a primary deficit of the midface, and fifteen (15) participants with a primary deficit of the lower face (chin, lips) as assessed by the Treating Investigator. Primary deficit is defined as facial third requiring more intense treatment or volumes of HA.

Treatment:

Device: Restylane Injectables